Cytokinetics Q3 net loss narrows as net product revenue rises

Overview

• U.S. cardiovascular biopharma's Q3 net product revenue reached $44.5 mln, driven by MYQORZO launch

• Company reported Q3 net loss narrowed to $190.1 mln from $306.2 mln a year ago

• Higher R&D and launch-related costs drove increased operating expenses in the quarter

Outlook

• Cytokinetics reaffirms 2026 GAAP R&D and SG&A expense guidance of $860 mln to $890 mln

• Company plans to submit supplemental NDA for aficamten in nHCM in Q4 2026

• Cytokinetics expects to launch MYQORZO in UK in Q4 2026 and more countries in 2027

Result Drivers

• MYQORZO LAUNCH MOMENTUM - Co cited growing adoption of MYQORZO in the U.S. and expanded access internationally as key drivers of Q3 revenue

• LAUNCH-RELATED COSTS - Higher selling, general and administrative expenses were mainly due to costs tied to the commercial launch of MYQORZO and increased personnel costs

• CLINICAL TRIAL ACTIVITY - Increased research and development expenses were driven by higher clinical trial activity and personnel costs

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 20 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Cytokinetics, Incorporated is $107.50, about 72.5% above its November 3 closing price of $62.31

Reuters Recommended Reads

• Nov 2 - Neurocrine Biosciences Q3 revenue jumps 41% on strong INGREZZA, CRENESSITY, VYKAT XR demand

• Nov 2 - Vertex Pharmaceuticals' Q3 revenue slightly beats estimates, outlook raised

• Nov 3 - Amgen Q3 revenue beats expectations on higher volumes

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)